The Medicines Company Finally Prevails in Angiomax patent fight with US PTO
This article was originally published in Scrip
Executive Summary
Following years of litigation, The Medicines Company has won its battle with the US Patent and Trademark Office after a US district court judge ordered the PTO to consider the Medicine Company's patent term extension application for Angiomax (bivalirudin) "timely filed".